Endothelial cell-derived plasmin promotes human glioma cell proliferation

Journal of Neuroimmunology

Volumn 276, Issue 1-2, 2014, Pages 58-63

  Luo, Ran ^a   Chen, Qianxue ^a   Tian, Daofeng ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Apoptosis; Endothelia; Glioma; Plasminogen; Protease activated receptor 2; TGF

Indexed keywords

INTERLEUKIN 6; PLASMINOGEN; PROTEINASE ACTIVATED RECEPTOR 2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; INTERFERON INDUCING AGENT; PLASMIN; POLYINOSINIC POLYCYTIDYLIC ACID;

ADOLESCENT; ADULT; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; TH17 CELL; UPREGULATION; ANALYSIS OF VARIANCE; BRAIN TUMOR; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOMA; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIN; FLOW CYTOMETRY; GLIOMA; HUMANS; INTERFERON INDUCERS; MALE; MIDDLE AGED; POLY I-C; RECEPTOR, PAR-2; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84908542802     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.08.613     Document Type: Article

References (19)

1. Alderton G.K. Tumorigenesis: the origins of glioma. Nat. Rev. Cancer 2011, 11:627.
2. Altrogge L.M., Monard D. An assay for high-sensitivity detection of thrombin activity and determination of proteases activating or inactivating protease-activated receptors. Anal. Biochem. 2000, 277:33-45.
3. Dutra-Oliveira A., Monteiro R.Q., Mariano-Oliveira A.a. Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines. Biochem. Biophys. Res. Commun. 2012, 421:221-227.
4. Feichtenbeiner A., Haas M., Buttner M., Grabenbauer G., Fietkau R., Distel L. Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters. Cancer Immunol. Immunother. 2014, 63:111-119.
5. He D., Li H., Yusuf N., Elmets C.A., Li J., Mountz J.D., Xu H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 2010, 184:2281-2288.
6. Holfeld J., Tepeköylü C., Kozaryn R., Urbschat A., Zacharowski K., Grimm M., Paulus P. Shockwave therapy differentially stimulates endothelial cells: implications on the control of inflammation via Toll-like receptor 3. Inflammation 2014, 37:65-70.
7. Imaizumi T., Yoshida H., Nishi N., Sashinami H., Nakamura T., Hirashima M., Ohyama C., Itoh K., Satoh K. Double-stranded RNA induces galectin-9 in vascular endothelial cells: involvement of TLR3, PI3K, and IRF3 pathway. Glycobiology 2007, 17:12C-15C.
8. Jenkins G. The role of proteases in transforming growth factor-beta activation. Int. J. Biochem. Cell Biol. 2008, 40:1068-1078.
9. Kim M.S., Jo H., Um J.Y., Yi J.M., Kim D.K., Choi S.C., Kim T.H., Nah Y.H., Kim H.M., Lee Y.M. Agonists of proteinase-activated receptor 2 induce TNF-alpha|secretion from astrocytoma cells. Cell Biochem. Funct. 2002, 20:339-345.
10. Liu Z.Q., Wu Y., Song J.P., Liu X., Liu Z., Zheng P.Y., Yang P.C. Tolerogenic CX3CR1+ B cells suppress food allergy-induced intestinal inflammation in mice. Allergy 2013, 68:1241-1248.
11. Luo R., Wang X., Dong Y., Wang L., Tian C. Activation of protease-activated receptor 2 reduces glioblastoma cell apoptosis. J. Biomed. Sci. 2014, 21:25.
12. Nava S., Dossena M., Pogliani S., Pellegatta S., Antozzi C., Baggi F., Gellera C., Pollo B., Parati E.A., Finocchiaro G., Frigerio S. An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. PLoS ONE 2012, 7:e52301.
13. Pesce B., Soto L., Sabugo F., Wurmann P., Cuchacovich M., López M.N., Sotelo P.H., Molina M.C., Aguillón J.C., Catalán D. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 2013, 171:237-242.
14. Schuler P.J., Bendszus M., Kuehnel S., Wagner S., Hoffmann T.K., Goldbrunner R., Vince G.H. Urokinase plasminogen activator, uPAR, MMP-2, and MMP-9 in the C6-glioblastoma rat model. In Vivo 2012, 26:571-576.
15. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 2013, 1:32-42.
16. Sethi R.V., Giantsoudi D., Raiford M., Malhi I., Niemierko A., Rapalino O., Caruso P., Yock T.I., Tarbell N.J., Paganetti H., MacDonald S.M. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. Int. J. Radiat. Oncol. Biol. Phys. 2014, 88:655-663.
17. Sun X., Tse L.V., Ferguson A.D., Whittaker G.R. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J. Virol. 2010, 84:8683-8690.
18. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., Bover L., Hanabuchi S., Khalili J., Marinova E., Zheng B., Littman D.R., Liu Y.J. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4793-4798.
19. Wang B.Q., Zhang C.M., Gao W., Wang X.F., Zhang H.L., Yang P.C. Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J. Cancer Res. Clin. Oncol. 2011, 137:1525-1533.